New strategies in engineering T-cell receptor gene-modified T cells to more effectively target malignancies
TM Schmitt, IM Stromnes, AG Chapuis… - Clinical cancer …, 2015 - AACR
TM Schmitt, IM Stromnes, AG Chapuis, PD Greenberg
Clinical cancer research, 2015•AACRThe immune system, T cells in particular, have the ability to target and destroy malignant
cells. However, antitumor immune responses induced from the endogenous T-cell repertoire
are often insufficient for the eradication of established tumors, as illustrated by the failure of
cancer vaccination strategies or checkpoint blockade for most tumors. Genetic modification
of T cells to express a defined T-cell receptor (TCR) can provide the means to rapidly
generate large numbers of tumor-reactive T cells capable of targeting tumor cells in vivo …
cells. However, antitumor immune responses induced from the endogenous T-cell repertoire
are often insufficient for the eradication of established tumors, as illustrated by the failure of
cancer vaccination strategies or checkpoint blockade for most tumors. Genetic modification
of T cells to express a defined T-cell receptor (TCR) can provide the means to rapidly
generate large numbers of tumor-reactive T cells capable of targeting tumor cells in vivo …
Abstract
The immune system, T cells in particular, have the ability to target and destroy malignant cells. However, antitumor immune responses induced from the endogenous T-cell repertoire are often insufficient for the eradication of established tumors, as illustrated by the failure of cancer vaccination strategies or checkpoint blockade for most tumors. Genetic modification of T cells to express a defined T-cell receptor (TCR) can provide the means to rapidly generate large numbers of tumor-reactive T cells capable of targeting tumor cells in vivo. However, cell-intrinsic factors as well as immunosuppressive factors in the tumor microenvironment can limit the function of such gene-modified T cells. New strategies currently being developed are refining and enhancing this approach, resulting in cellular therapies that more effectively target tumors and that are less susceptible to tumor immune evasion. Clin Cancer Res; 21(23); 5191–7. ©2015 AACR.
AACR